All-trans retinoic acid (ATRA) is the only clinically useful differentiating agent, being used in the treatment of acute promyelocytic leukemia (APL). The use of ATRA in other types of acute myelogenous leukemia (AML) calls for the identification of novel strategies aimed at increasing its therapeutic activity. Here, we provide evidence that pharmacological inhibition of the mitogen-activated protein kinase, p38a, or silencing of the corresponding gene sensitizes APL and AML cell lines, as well as primary cultures of AML blasts to the anti-proliferative and cyto-differentiating activity of ATRA and synthetic retinoids. P38a inhibits ligand-dependent transactivation of the nuclear retinoic acid receptor, RARa, and the derived chimeric protein expressed in the majority of APL cases, PML-RARa. Inhibition is the consequence of ligand-independent binding of p38a, which results in stabilization of RARa and PML-RARa via blockade of their constitutive degradation by the proteasome. The inhibitory effect requires a catalytically active p38a and direct physical interaction with RARa and PML-RARa. Ser-369 in the E-region of RARa is essential for the binding of p38a and the ensuing functional effects on the activity of the receptor.
INTRODUCTION
All-trans retinoic acid (ATRA) causes 85% complete remissions in acute promyelocytic leukemia (APL) patients when administered in combination with chemotherapy. 1 --4 In APL, ATRA induces terminal differentiation along the granulocytic pathway and this is likely to be one of the mechanisms for its therapeutic effects, 5 --7 although alternative hypotheses have been recently proposed. 8 --10 In other types of acute myelogenous leukemia (AML) blasts, the differentiation signal provided by ATRA is less effective despite expression of RARa, the main retinoid receptor of the hematopoietic system (E Garattini, unpublished observations).
One strategy to improve the efficacy of retinoids is to identify non-retinoid compounds that enhance the activity of ATRA, 11 --15 focusing on the mechanisms controlling the stability/activation of the nuclear retinoid receptors expressed in the AML blast. An important mechanism modulating the activity of the RARcontaining transcriptional complexes is phosphorylation of RARs 16 --18 and accessory proteins, 18 such as co-repressors and co-activators. 19 The mitogen-activated kinase p38a (p38a), cyclin-dependent kinase 7 and mitogen-and stress-activated kinase (MSK1) stand out as determinants in the process. 20 --22 The phosphorylation state of RARa influences not only the activity but also proteasome-dependent degradation of the receptor, whose blockade has been associated with ATRA-dependent differentiation of APL and AML cells. 23 --25 P38a is often increased and/or activated in AML blasts 26, 27 and it represents an important pharmacological target as well as a potential determinant of ATRA sensitivity in these cells. Here, we demonstrate that p38a inhibition or suppression enhances sensitivity to ATRA not only in APL but also in other types of AML blasts and defines the underlying molecular mechanisms.
MATERIALS AND METHODS

Reagents and plasmids
PD169316, PD98059, SP600125 and the proteasome inhibitor, MG132, ATRA and cycloheximide were from Sigma (St Louis, MO, USA). The following plasmid constructs were used: hRARa and PML-RARa; 23 hRARaS77A (S77A), 19 hRARaS369A (S369A); 28 hRARaL342T (L342T) and hRARaP345G/D346A (P345G/D346A); 22 hPML-RARaS581A (S581A, obtained by site-directed mutagenesis using standard methods was inserted in PSG5); hPML-RARaS873A (S873A); 10 p38aMAPK (p38a); 19 KRSPA Flag p38 (dnP38); 19 GST-p38a andGST-DNp38a; 29 HA-WTp38a and HA-Y258A-p38a (kind gifts from S Keyse and R Dickinson, Dundee, UK); HA-I116A-p38a and HA-Q120A-p38a (kind gifts from EJ Goldsmith, Dallas, TX, USA); Flag-p38a(CD mut ) (mCD), 30 Flag-p38a(ED mut ) (mED), 30 b2RARE-luc and DR5-tk-luc;
19 hRARaS77A (S77A); 19 GST-AB-RARa (GST-AB) and GST-DEF-RARa (GST-DEF). 22 
Cells
NB4,
31 HL-60, 32 OCI-AML3, 33 COS-7 (ref. 23) cells, RARa À/À mouse embryo fibroblasts (MEF) 20 and freshly isolated AML blasts from the peripheral blood of four AML patients (Supplementary Table I) were cultured as described. 23 All patients gave informed consent for sample collection. The protocol for the collection of leukemic blasts from AML patients was approved by the local ethical committee. To generate NB4 cells silenced for p38a or expressing a dominant-negative form of the kinase, NB4 and HL-60 were infected with the appropriate viral stocks (viral titers were in the range of 1.0 --1.5 Â 10 9 TU/ml), according to the instructions of the manufacturer (Open Biosystems, Huntsville, AL, USA). The following viral stocks were used: a 1:1 mixture of pLKO transfer lentiviral vectors (Open Biosystems) containing two small hairpin RNAs targeting human p38a (nr 6; 5 0 -CCTGACCTATGATGAAGTCAT-3 0 and nr7*; 5 0 -GCTGAATGGATGCATT ACAA-3 0 ) and the reporter gene, GFP (green fluorescent protein). The mixture was used to infect NB4 cells along with puro R pLKO empty vector (Sigma) in a 10:1 ratio. Negative control NB4 cells were obtained by infection with the puro R pLKO empty vector alone. NB4 cells were subsequently selected in puromycin (1 mg/ml). The NB4 cells expressing the dominant-negative form of p38a were generated as follows. The complementary DNA encoding the dominant-negative form of p38a was amplified by PCR using the BamHI containing oligonucleotide, 5 0 -GG GGATCCGCCGCCACCATGTCTCAGGAGAGGCCCACGT-3 0 (underlined: nucleotides 482 --503 of NM_139012, sense orientation) and the SpeI containing oligonucleotide, 5 0 -CCACTAGTTCAGGACTCCATCTCTTCTTGG-3 0 (underlined: nucleotides 1564 --1543 of NM_139012, antisense orientation) from dnP38and inserted in the pWPXLd lentiviral vector (Addgene plasmid Figure 1 . Inhibition of p38a increases the anti-proliferative and differentiating activity of ATRA in NB4 cells. (a) Left: NB4 cells were treated with vehicle (dimethyl sulfoxide (DMSO)), PD169316 (PD, 10 mM), ATRA (0.01 mM, solid circles; 1.0 mM, solid triangles) or PD169316 þ ATRA (PD þ ATRA, 10 mM and 0.01 mM, respectively) and the number of viable cells counted after Trypan blue staining. Right: NB4 cells were treated with ATRA (0.1or 1.0 mM) and the indicated compounds, each at 1.0 mM, alone or in combination, for 4 days. NBT-reducing activity was measured and values are the mean ± s. Pull-down, immunoprecipitation and far-Western experiments were as described. 23 For the pull-down experiments, 23 we used GST-p38a and GSTDNp38a. For the immunoprecipitation experiments in NB4 cells, anti-RARa antibodies 23 were used. For other immunoprecipitations, we transfected hRARa and PML-RARa and HA-WTp38a in COS-7 cells. Immunoprecipitations were performed with anti-RARa 23 or anti-HA antibodies (Sigma). In the last case, proteins were precipitated with HA-Sepharose beads (Amersham, Little Chalfont, UK). Immunoprecipitated or pulled down proteins were subjected to western blot analysis using anti-RARa, anti-HA, anti-p38a (Cell Signaling, Danvers, MA, USA) or anti-phospho-p38a (Cell Signaling) antibodies. FarWestern experiments were performed in COS-7 cells transfected with hRARa and hRARaS77A. Cell extracts were immunoprecipitated with anti-RARa antibodies and western blots were developed with anti-p38a and anti-RARa antibodies. Other western blots were developed with anti-b-actin, anticEBPa,b, anti-STAT1a, anti-p21 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-paxillin antibodies (anti-paxillin (PXN), Cell Signaling). ChIP experiments were as described. 20 Control ChIPs were performed without antibody and with isotype-matched IgGs. PML-RARa was immunoprecipitated with rabbit polyclonal antibodies against PML (H-238, Santa Cruz Biotechnology). RARa was immunoprecipitated with monoclonal antibodies recognizing the N-terminus of RARa (MAB10a1-A1), 34 which is absent in PML-RARa. p38a was immunoprecipitated with anti-p38a antibodies (Cell Signaling). Immunoprecipitated DNA was amplified by quantitative PCR using a Light Cycler realtime PCR system (Roche Applied Science, Ltd, Monza, Italy). 13, 20 Occupancy of the promoters was calculated by normalizing the PCR signals from the IP samples to the signals obtained from the input DNA. The specificity of the experimental conditions was checked in the absence of antibodies, with isotype-matched control IgG and with the promoter of a control 36BA gene. 17, 20, 35 Luciferase assays, fluorescence-activated cell sorter and quantitative PCR analyses
The transcriptional activity of RARa and PML-RARa was determined after transient transfection in COS-7 cells as already described. 23 Fluorescence-activated cell sorter (FACS) analyses were performed as detailed. 23 Quantitative PCR analyses were performed with specific Taqman assays for the RARB (Hs00233407_m1), TGM2 (Hs00190278_m1), PXN (Hs00257873_s1) and CY26A1 (Hs00175627_m1) mRNAs after reverse transcription according to the instructions of the manufacturer (Applied Biosystems, Carlsbad, CA, USA).
RESULTS
Pharmacological inhibitors of p38a enhance retinoid-dependent growth inhibition and differentiation of AML cells We evaluated the consequences of p38a inhibition on ATRAinduced growth suppression and myeloid differentiation 36 of the APL-derived NB4 cell line, 31 which expresses the specific PML-RARa fusion product as well as the product of the normal RARa allele. Although inhibition of p38a by PD169316 (10 mM) exerted minor effects on the growth of NB4 cells, it enhanced the antiproliferative action of ATRA at sub-optimal concentrations (Figure 1a , left). PD169316 exerted a similar potentiating effect on retinoid-dependent induction of the myeloid marker, NBT-reductase 24 ( Figure 1a , right). This last phenomenon was replicated by the other p38a inhibitor, SB203580 (ref. 37) (data not shown). PD98059 and SP600125, two selective inhibitors of extracellular signal-regulated kinases and c-Jun N-terminal kinases, respectively, exerted very limited and opposite effects on the induction of NBT-reductase activity by ATRA. PD169316 positively modulated retinoid-dependent expression of the other differentiation-associated markers, CD11b, CD11c, STAT1a, cEBPb and PXN (Figures 1b and c) Figure 1c ), was even more powerful than ATRA in inducing STAT1a, cEBPb and PXN, when the compound was combined with PD169316. In the same experimental conditions, the RARg agonist, CD437 (ref. 39) Figure 1c), and the RARb agonist, BMS641 (refs. 40,41) (data not shown), were ineffective or much less effective than ATRA and AM580. The observed phenomena were likely to involve modulation of RARa and/or PML-RARa activity by PD169316, as demonstrated by enhanced upregulation of the direct retinoid target genes, 42 RARB, (Pt 1), using CD11b, CD11c and CD38 (Figure 2a) . The blasts of a second retinoid-responsive patient (Pt 2) were refractory to the enhancing effect of PD169316 (Supplementary Figure 2A) . At present, we do not know whether this is the result of low or absent p38a expression. Primary cultures of three other AML patients were left unaffected by either ATRA or PD169316 þ ATRA (data not shown). Thus, the enhancing effect of PD169316 is not limited to APL cells and is observed in a fraction of other AML types. In non-APL cells, responsiveness to ATRA is necessary but not sufficient for the potentiating effects observed after p38a inhibition.
There is growing evidence, that cytoplasmic relocalization of nucleophosmin 1 (NPM1), 48 --50 is a determinant of retinoid responsiveness in AML blasts. 51, 52 Hence, we evaluated the effect of ATRA and/or PD169316 in OCI-AML3, a cell line expressing a mutated/cytoplasmic version of NPM1. 33 Treatment with ATRA (0.01 mM) inhibited the growth of OCI-AML3 cells (Figure 2b ). This anti-proliferative effect was magnified by co-treatment with PD169316 (10 mM). Consistent with enhanced growth inhibition, PD169316 þ ATRA caused a superior induction of p21 relative to ATRA alone. 52 This was accompanied by enhanced expression of CD11c, STAT1a, cEBPa, 53 cEBPb and PXN. The blasts of Pt 3 expressing the same mutated form of NPM1 (ref. 49) as OCI-AML3 cells responded to PD169316 þ ATRA with enhanced upregulation of CD11b, CD11c and CD38 (Supplementary Figure 2B) . Enhanced upregulation of the two markers, STAT1a and cEBPb by PD169316 þ ATRA, was also observed in the AML blasts of a patient showing a 3:5 translocation, involving NPM1 and leading to cytoplasmic relocalization of the fusion product 48 --50 ( Supplementary Figure 2c) . Silencing or functional inactivation of p38a potentiates ATRA activity in NB4 cells As p38a pharmacological inhibitors are not entirely specific, we evaluated whether functional inhibition or silencing of the kinase resulted in enhancement of retinoid-dependent differentiation. We infected NB4 cells with lentiviral constructs containing a dominant-negative form of p38a (NB4-dnP38) or a p38a-targeting small hairpin RNA (NB4-shP38) and relative negative controls (NB4-dnC; NB4-shC). As expected, phosphorylation/activation of the kinase by ATRA was reduced in NB4-dnP38 cells relative to the NB4-dnC counterparts (Figure 3a, left) . Consistent with silencing of the relative gene, the levels of p38a were significantly reduced in NB4-shP38 cells as compared with the NB4-shC controls (Figure 3a , right). This was accompanied by upregulation of the myeloid marker, Stat1a.
The anti-proliferative effect of ATRA was significantly higher in both NB4-dnP38 and NB4-shP38 cells than in the corresponding NB4-dnC and NB4-shC controls (Figure 3b ). Increased sensitivity of NB4-dnP38 and NB4-shP38 cells extended to ATRA-dependent induction of myeloid differentiation markers (Figure 3c ), and direct retinoid target genes (Figure 3d ). Once again, the involvement of RARa or PML-RARa in the observed effects was confirmed for STAT1 and cEBPb with AM580 ( Figure 3c ). Incomplete selectivity of CD437 for RARg and the residual activity of the agonist on RARa 54 is likely to cause the upregulation of cEBPb and STAT1 observed in NB4-dnP38 cells.
RARa and PML-RARa transcriptional activity is inhibited by p38a To elucidate the mechanisms underlying the potentiating effects of p38a inhibition/suppression, we performed studies in COS-7 cells.
14,39 Expression plasmids encoding p38a and RARa or PMLRARa were transiently transfected along with the retinoidresponsive reporter, b2RARE-luc. 23 Time-course experiments demonstrated that the action of p38a was biphasic (Figure 4a) . Indeed, p38a overexpression caused an early (15 min) and (24 h ) and long-lasting inhibitory effect. The early and transient activation of RARa by ATRA correlated with short-term stimulation of p38a (see also Figure 6c ), which has been proposed as an event sensitizing the receptor to the ligand. 20 We focused on the late inhibitory action of p38a, as it correlated with the results obtained in AML blasts. Overexpression of p38a caused a dose-dependent inhibitory effect on the activation of RARa by ATRA (Figure 4b) . A similar inhibition was observed if b2RARE-luc was substituted by the other reporter, DR5tk-RARE-luc (Supplementary Figure 3A) . Inhibition required an active kinase, as PD169316 reverted the effect afforded by p38a on both RARa and PML-RARa (Supplementary Figure 3B) . The observation was supported by overexpression of a catalytically inactive form of p38a (dnP38) (Supplementary Figure 3C) . p38a Controls the steady-state levels of unliganded RARa and PML-RARa directly modulating the degradation of the two receptors: indirect effects on ATRA-dependent downregulation The distinct processes of ligand-independent and ligand-dependent degradation of RARa and PML-RARa are both controlled by the proteasome. 23, 24, 35 Thus, we evaluated the involvement of p38a in either process using forced expression of the protein in COS-7 cells.
Overexpression of p38a caused a dose-dependent decrease in the amounts of RARa and PML-RARa in the absence of ATRA (Figure 4c ). As illustrated in the case of RARa (Figure 4d) , the phenomenon was reversed by the proteasome inhibitor, MG132. This indicated that p38a regulates the basal turnover of the two unliganded receptors via control of their degradation by the proteasome. Destabilization of the two unliganded receptors by p38a has indirect consequences on the degradation pathway activated by the ligand. In fact, treatment of p38a transfected COS-7 cells with ATRA resulted in further downregulation of RARa and PML-RARa relative to what was observed in empty vector transfected and untreated cells (Figures 4d and e) . The degradation of RARa/PML-RARa induced by p38a and enhanced by ATRA required a catalytically active enzyme, as both phenomena were blocked by PD169316 (Figure 4e ) and a dominant-negative form of p38a (Figure 4f ). This further supports the concept that ligandindependent degradation of the two receptors by p38a influences the ligand-dependent process as well.
The stabilizing action exerted by p38a inhibition was confirmed on endogenous RARa and PML-RARa in NB4 (Figure 5a ), OCI-AML3 (Figure 5b, left) , HL-60 (Supplementary Figure 1C) cell lines and blasts from Pt 4 (Figure 5b, right) . The involvement of p38a in the control of RARa and PML-RARa stability was validated by the observation that the steady-state levels of the two retinoid receptors were higher in NB4-dnP38 and NB4-shP38 cells than in the NB4-dnC and NB4-shC counterparts, both in the absence and in (Figure 5c ). In these cellular models, RARa and PML-RARa stabilization correlated with induction of the myeloid marker, STAT1a (Figures 5a and c) . All this is consistent with active p38a exerting an indirect and long-term negative effect on the ligand-dependent activation of RARa/PML-RARa, as well as downstream regulated targets, via increase in the basal degradation rate and turnover of the two receptors. The contention was corroborated by direct determination of RARa and PML-RARa half-life in NB4 cells with experiments involving inhibition of protein translation by cycloheximide. The half-life of RARa and PML-RARa was increased in NB4-dnP38 relative to NB4-dnC control cells (Figure 5d, upper) . Similarly, inhibition of p38a phosphorylation in NB4 cells challenged with PD169316 resulted in increased stability of the two proteins (Figure 5d , lower).
RARa and PML-RARa interact with p38a in a direct and ligand-independent manner Control of RARa and PML-RARa by p38a may implicate binding of the two unliganded receptors to the kinase, a fraction of which resides in the nucleus (Supplementary Figure 3D) . The existence of interactions between RARa or PML-RARa and p38a was sought for by immunoprecipitation experiments. To this purpose, we overexpressed RARa with/without p38a in COS-7 cells (Figure 6a , )) were transfected with a PML-RARa expression plasmid in the absence/presence of a p38a expression plasmid. Lower: COS-7 cells were co-transfected with a RARa expression plasmid and an expression plasmid containing an HA-tagged version of p38a. Cells were subsequently treated with ATRA (1.0 mM) for 16 h. Total cell extracts were immunoprecipitated with anti-RARa or anti-HA antibodies and control isotype-matched IgG, as indicated. The immunoprecipitates were subjected to western blot analysis with anti-RARa or anti-p38a antibodies. The levels of RARa, PMLRARa and p38a present in cell extracts before IP were determined in parallel by western blot analysis (input). (b) NB4 cells were treated with ATRA (1.0 mM) for 24 h. Total cell extracts were immunoprecipitated with anti-RARa antibodies. The immunoprecipitates were subjected to western blot analysis with anti-RARa or anti-p38a antibodies as in a. (c) COS-7 cells were transfected with expression plasmids for RARa and p38a as in a. Cells were treated with ATRA (1.0 mM) for the indicated amount of time. After IP with anti-RARa antibodies, the levels of p38a, phosphorylated/activated p38a and RARa were determined by western blot analysis. (d) Chromatin immunoprecipitation (ChIP) assays were performed using NB4 cells treated with vehicle or ATRA (0.1 mM) for the indicated amount of time. After IP with p38a, RARa and PML antibodies (see Materials and Methods), the RARE-containing regulatory regions of the RARa2, RARb2 and CYP26A1 genes were amplified by quantitative PCR. Values (% of inputs) are representative of two independent experiments. All our experiments included appropriate negative control ChIPs that were performed in the absence of an immunoprecipitating antibody or after IP with isotype-matched IgG. Further negative controls were performed with the promoter of the 36BA gene, which does not contain any retinoid response element. All these conditions were characterized by the absence of detectable signals upon quantitative PCR analysis. upper). Immunoprecipitation with an anti-RARa antibody resulted in co-precipitation of p38a only in cells overexpressing both proteins. Interaction was not affected by treatment of the cells with ATRA. By the same token, co-immunoprecipitation of PML-RARa and p38a was observed only in RARa À/À MEF cells co-transfected with the aberrant retinoid receptor and the kinase regardless of ATRA treatment (Figure 6a , middle). The interaction was confirmed when p38a, instead of RARa, was immunoprecipitated in complementary experiments involving an HA-tagged version of the kinase (Figure 6a, lower) . Further support to ligandindependent binding of the two receptors to the kinase was obtained by pull-down experiments with GST-tagged versions of p38a and RARa in COS-7 (Supplementary Figure 4A) , HL-60 and OCI-AML3 cells (data not shown). Final evidence was obtained on native p38a and RARa/PML-RARa in NB4 cells (Figure 6b ). Constitutive interaction of p38a and RARa was direct, as demonstrated by far-Western experiments (Supplementary Figure 4B) .
To evaluate whether a fraction of the total amount of p38a bound to RARa is in its phosphorylated/active form, we performed immunoprecipitation experiments in transfected COS-7 cells (Figure 6c ). Our results demonstrated that a detectable amount of phosphorylated p38a was bound to RARa in basal conditions. Treatment with the retinoid augmented the amounts of phosphorylated p38a interacting with RARa. This effect was transient and lasted for a maximum of 30 min, in line with shortterm activation of p38a. 20 The phenomenon may be caused by recruitment of free p38a to the receptor after ATRA-dependent phosphorylation or by ATRA-induced phosphorylation of the already bound kinase.
To support the functional relevance of our results, we performed ChIP assays in NB4 cells (Figure 6d ). We demonstrated ATRA-dependent recruitment of p38a to the RARE-containing regulatory regions of the retinoid-responsive genes, RARA2, RARB2 and CYP26A1. A very similar effect was observed in the case of RARa. In contrast, treatment with ATRA resulted in rapid detachment of PML-RARa. This was in line with the idea that RARa and PML-RARa compete for the same DNA sequences on the three retinoid target genes. The kinetics of p38a and RARa association with the regulatory regions of the three genes considered were very similar, consistent with binding of the kinase to the nuclear receptor.
Binding to RARa/PML-RARa of a catalytically active p38a is necessary for the inhibitory effect of the kinase To evaluate whether the modulating action of p38a on RARa and PML-RARa requires binding to the two receptors, we conducted studies with mutants of the kinase. Mutants of the CD (mCD) and ED (mED) domains, recognizing the D-docking site on protein substrates, 30, 55 abrogated binding to RARa (Figure 7a ). Identical phenomena were observed after mutation of Tyr-258 (Y258A), a residue stabilizing the structure of the interaction pocket responsible for the binding of p38a to another docking site (DEF domain) present on substrate proteins. 56 In contrast, two further mutations (I116A and Q120A) outside the canonicaldocking sites exerted no effect on p38a ability to interact with RARa. This correlated with the inability of mCD, mED and Y258A to inhibit ligand-dependent transactivation of RARa as well as PML-RARa (Supplementary Figure 5) . The mCD, mED and Y258A mutants were equally ineffective in inducing ligand-independent degradation of RARa and/or PML-RARa (Figure 7b ). Our results indicated that binding of p38a to RARa/PML-RARa is a prerequisite for the degradation and functional inhibition of the two receptors. Indeed, the dominant-negative and catalytically inactive form of p38a (dnP38) retained the ability to interact with both RARa and PML-RARa, whereas it lost the capacity to inhibit liganddependent transactivation and to induce ligand-independent degradation of the two receptors.
Ser-369 in the E-region of RARa is essential for the interaction with p38a and controls inhibition/degradation of the receptor by the kinase To define the regions of RARa (Figure 8a ) necessary for the binding to p38a, we performed pull-down experiments with GST-tagged versions of RARa. The A and B domains were devoid of binding activity, whereas the DEF regions of RARa contained the interface(s) necessary for the interaction with p38a (Figure 8b ). In agreement with the necessity of physical interaction between the two proteins for the observed functional effects, RARa mutants characterized by combined (DABRARa) or separate (DARARa and DBRARa) deletion of the A/B domains maintained transcriptional inhibition by p38a (Supplementary Figure 6A) . A similar effect was observed with a mutant devoid of the F region (DFRARa), which suggested that the domain was also dispensable for the binding to p38a. DARARa, DBRARa and DFRARa were degraded as effectively as the WT counterpart by p38a overexpression (Supplementary Figure 6B) . In conclusion, our results ruled out the A-, B-and F-domains of RARa as the regions involved in binding p38a. In addition, the domains do not influence functional inhibition and degradation triggered by the kinase.
Deletion mutants of the D-and E-regions of RARa could not be used for the same type of studies described above, as they are functionally inactive. Nevertheless, we hypothesized that the Eregion may be more important than the D-region in the observed effects, as it is an interaction platform for many proteins including co-activators such as SRCs 19 and it is characterized by a number of helices whose conformation is modulated by phosphorylation. 18 For these reasons, we considered site-directed mutants of the Edomain that did not affect the functional activity of RARa significantly. We considered the L342T mutation in loop L8-9, 22 the double mutation P345G/D346A affecting the first two residues of helix 9 (ref. 22) and the S369A mutation blocking the phosphorylation of Ser-369, which is an established target of PKA 28, 57 and MSK1. 20 Pull-down experiments demonstrated that the L342T and P345G/D346A mutations maintained the ability of RARa to interact Precipitates were subjected to western blot analysis with anti-p38a or anti-GST antibodies. The levels of p38a present in cell extracts before the pull-down procedure were determined (input). AB, GST-tagged AB region of hRARa; DEF, GST-tagged DEF regions of hRARa; WT, GST-tagged full-length hRARa. (c) Extracts of COS-7 cells transfected with constructs encoding the wild type and the indicated mutants of RARa were pulled-down after incubation with a GST-tagged version of p38a and glutathione-coupled Sepharose beads. Precipitates were subjected to western blot analysis with anti-RARa or anti-p38a antibodies. The levels of RARa present in cell extracts before the pull-down procedure were determined in parallel by western blot analysis (input). (d) COS-7 cells were transfected with plasmid constructs encoding the wild type (WT) and the indicated mutants of RARa and PML-RARa as well as p38a in the presence of the retinoid-responsive reporter construct, DR5-tk-Luc. At 24 h after transfection, cells were treated for a further 16 h with ATRA (1.0 mM). Firefly and renilla luciferase activities were measured in cell extracts and the results are expressed as fold induction relative to the corresponding vehicle-treated control after normalization for transfection efficiency, using renilla luciferase activity. Each value is the mean±s.d. of three replicate cultures. (e) COS-7 cells were transfected with the indicated mutants of RARa or PML-RARa and treated as described in d. The levels of RARa, PML-RARa, p38a and b-actin were determined by western blot analysis. p38a binds and regulates RARa and PML-RARa M Gianni et al with p38a (Figure 8c ). In contrast, the S369A mutant lost the ability to bind to p38a. Thus, the E-domain is involved in p38a binding to RARa and Ser-369 is a crucial determinant of this interaction. In the same experimental conditions (Figure 8d ), the RARa S369A mutant was refractory to p38a inhibition in the functional studies performed with transfected COS-7 cells. Resistance was also observed in the corresponding (S873A) PML-RARa mutant. 10 This indicates that blocking physical interaction between p38a and RARa/PML-RARa suppresses the inhibitory effect of the kinase on the ligand-dependent transcription of the two receptors.
We established whether physical interaction is required for the degradation of unliganded RARa/PML-RARa by p38a (Figure 8e ). In the absence of ATRA, both the S369A mutant of RARa and the S873A mutant of PML-RARa were resistant to p38a-induced degradation. This is consistent with the observed correlation between induced basal degradation of the two receptors and suppression of functional activity by p38a. Upon treatment with ATRA, the behavior of S369A was different from that of S873A. In fact, the RARa mutant was still sensitive to degradation by ATRA, whereas the PML-RARa mutant was resistant to this effect (Figure 8e ). At present, we do not have any explanation for this dichotomy. Nevertheless, this last result had already been reported 10 and suggests that differences in the conformation of the RARa and PML-RARa E-domain influence ligand-dependent degradation.
DISCUSSION
In this report, we demonstrate that inhibition or silencing of p38a, results in increased retinoid-dependent growth inhibition and differentiation of the PML-RARa-positive NB4 and the PML-RARa-negative HL-60 cells lines. Similar phenomena were also evident in AML contexts other than APL. Thus, p38a inhibition increases the differentiating and anti-proliferative effects of ATRA in retinoid-sensitive APL and a fraction of AML blasts. The latter group includes AML cases characterized by cytosolic localization of NPM1, an emerging molecular marker of retinoid sensitivity. 51 The molecular mechanisms underlying the facilitating action of p38a inhibition/suppression on the differentiating activity of ATRA in AML cells involve a specific effect on retinoid receptors. In fact, p38a causes long-term inhibition of the ligand-dependent transcriptional activation of RARa. This is the consequence of an increase in the constitutive and proteasome-dependent degradation of RARa, which results in increased turnover and decreased steady-state levels of the receptor. In APL cells, p38a acts not only on RARa but also on the oncogenic translocation product, PML-RARa. Inhibition of p38a may cause a preferential increase in the relative amounts and activity of RARa over those of PML-RARa, as the former protein is characterized by a longer half-life than the latter one, both in basal conditions and following treatment with ATRA. 58 Furthermore, ATRA recruits RARa to the regulatory regions of target genes, while it releases PML-RARa from the same binding sites. 13 An increased RARa/PML-RARa ratio may diminish the suppressive effects of PML-RARa on common retinoid target genes involved in differentiation and/or growth inhibition.
Negative regulation of RARa and PML-RARa by p38a is accompanied by interaction of the kinase with either receptor. Binding of p38a is direct, ligand independent and does not require a catalytically active form of the kinase. We identify Ser-369 in the E-region of RARa as a residue involved in p38a docking. All our results are consistent with the idea that this interaction is essential for the functional inhibition exerted by p38a on the two retinoid receptors. It is unclear whether Ser-369 needs to be phosphorylated to permit kinase binding. As Ser-369 is a phosphorylation target for PKA and MSK1, 20 one of the two kinases may have a role in p38a binding to unliganded RARa and/or PML-RARa. This is a possibility in the case of PKA, whereas the involvement of MSK1 is unlikely, as the kinase is transiently and rapidly activated by p38a itself only after treatment with ATRA. It must be emphasized that Ser-369 exerts other functions besides control of p38a binding to RARa, as the S369A mutant lost also its ability to respond to the transient and early increase in ligand-dependent transactivation afforded by p38a overexpression in COS-7 cells (Supplementary Figure 6C) . This is likely to be the result of a phosphorylation event triggered by MSK1, which is permissive for the transcriptional activity of RARa. 20 A fraction of the p38a bound to the unliganded receptors is in its catalytically active state. This fraction is rapidly and transiently augmented after challenge with ATRA. Hence, activation of the bound kinase consists of two components: a constitutive and a short-lived ligand-dependent one. We propose that the first component influences the basal turnover of RARa (and PML-RARa) by controlling the degradation rate of the protein. As RARa is characterized by a number of predicted p38a-target residues that are conserved in PML-RARa, direct phosphorylation of the retinoid receptor by the bound kinase may represent the event signaling degradation. However, at present, the putative residues targeted by the kinase have not yet been identified. In fact, phosphorylation of Ser-77 is not altered by p38a overexpression in COS-7 cells (data not shown). In addition, mutation of Ser-77, Ser-445, Ser-449, Ser-456 and Ser-461 to Ala in the F domain do not have any influence on the inhibitory effect afforded by p38a overexpression on RARa (M Gianni, unpublished observations). Alternatively, it is possible that constitutive degradation of RARa is indirect and follows degradation of other components of the transcription complex. In this case, we can envisage that the two retinoid receptors act as anchoring platforms for p38a, allowing the phosphorylation and degradation of other components of the unliganded retinoid receptor complex, such as the corepressor SMRT. 59 In conclusion, our results add a further layer of complexity to the mechanisms controlling retinoid receptors' activity and provide the rationale for the use of novel strategies in the treatment of AML patients.
